An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Lauren M., Wilkinson, Rachel, Altan, Mehmet, Toki, Maria, Carvajal-Hausdorf, Daniel E., McGuire, John, Ehrlich, Barbara E., Rimm, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847580/
https://www.ncbi.nlm.nih.gov/pubmed/29560416
http://dx.doi.org/10.1038/s41523-018-0057-7
Descripción
Sumario:Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.

Ejemplares similares